@moleculexyz.bsky.social
DeSci biopharma IP tokenization protocol.
Fund & shape early-stage research ideas at https://www.molecule.xyz/
Fund & shape early-stage research ideas at https://www.molecule.xyz/
Track, trade, + explore $VITAFOXO here: molecule.xyz/ipts/vitafoxo
Get VITAFOXO on Base | Live USD Price, Research Progress & Science Token Trading
Buy and track VITAFOXO via the latest price charts and scientific progress. biotech research IP token with governance rights. Live data on Molecule.xyz.
molecule.xyz
November 28, 2025 at 12:35 PM
Track, trade, + explore $VITAFOXO here: molecule.xyz/ipts/vitafoxo
The project moves through a staged development plan:
> refining oligo design, validating FOXO3 splice-shift in disc cells, and advancing toward human-relevant models.
> all progress will be shared transparently through Molecule Labs and linked directly to the $VITAFOXO token page.
> refining oligo design, validating FOXO3 splice-shift in disc cells, and advancing toward human-relevant models.
> all progress will be shared transparently through Molecule Labs and linked directly to the $VITAFOXO token page.
November 28, 2025 at 12:35 PM
The project moves through a staged development plan:
> refining oligo design, validating FOXO3 splice-shift in disc cells, and advancing toward human-relevant models.
> all progress will be shared transparently through Molecule Labs and linked directly to the $VITAFOXO token page.
> refining oligo design, validating FOXO3 splice-shift in disc cells, and advancing toward human-relevant models.
> all progress will be shared transparently through Molecule Labs and linked directly to the $VITAFOXO token page.
The team is developing antisense oligonucleotides (AONs) that precisely redirect FOXO3 splicing.
The goal:
> restore healthier FOXO3 activity → reduce senescence → slow structural disc decline.
> A precise, scalable route to drugs that extend healthspan.
The goal:
> restore healthier FOXO3 activity → reduce senescence → slow structural disc decline.
> A precise, scalable route to drugs that extend healthspan.
November 28, 2025 at 12:35 PM
The team is developing antisense oligonucleotides (AONs) that precisely redirect FOXO3 splicing.
The goal:
> restore healthier FOXO3 activity → reduce senescence → slow structural disc decline.
> A precise, scalable route to drugs that extend healthspan.
The goal:
> restore healthier FOXO3 activity → reduce senescence → slow structural disc decline.
> A precise, scalable route to drugs that extend healthspan.
Degenerative disc disease affects hundreds of millions and is a leading cause of disability.
But current treatments only address symptoms, not the cellular pathways that cause discs to break down.
> FOXO3 is a longevity-linked gene that helps cells resist stress and maintain function.
But current treatments only address symptoms, not the cellular pathways that cause discs to break down.
> FOXO3 is a longevity-linked gene that helps cells resist stress and maintain function.
November 28, 2025 at 12:35 PM
Degenerative disc disease affects hundreds of millions and is a leading cause of disability.
But current treatments only address symptoms, not the cellular pathways that cause discs to break down.
> FOXO3 is a longevity-linked gene that helps cells resist stress and maintain function.
But current treatments only address symptoms, not the cellular pathways that cause discs to break down.
> FOXO3 is a longevity-linked gene that helps cells resist stress and maintain function.
Track, trade, + explore $RLV here:molecule.xyz/ipts/rlv
Get RLV on Base | Live USD Price, Research Progress & Science Token Trading
Buy and track RLV via the latest price charts and scientific progress. biotech research IP token with governance rights. Live data on Molecule.xyz.
molecule.xyz
November 26, 2025 at 12:26 AM
Track, trade, + explore $RLV here:molecule.xyz/ipts/rlv
All milestone updates, formulation decisions, and manufacturing phases are logged through Molecule Labs and linked directly to the $RLV token page.
> a compliant, hemp-derived therapeutic built for reproducibility, oversight, and translation.
> a compliant, hemp-derived therapeutic built for reproducibility, oversight, and translation.
November 26, 2025 at 12:26 AM
All milestone updates, formulation decisions, and manufacturing phases are logged through Molecule Labs and linked directly to the $RLV token page.
> a compliant, hemp-derived therapeutic built for reproducibility, oversight, and translation.
> a compliant, hemp-derived therapeutic built for reproducibility, oversight, and translation.
The core hypothesis:
> a reproducible ratio of cannabinoids + terpenes can modulate pain pathways with consistent, clinically meaningful outcomes.
A mechanism grounded in compound interaction, and measurable biological signaling.
> a reproducible ratio of cannabinoids + terpenes can modulate pain pathways with consistent, clinically meaningful outcomes.
A mechanism grounded in compound interaction, and measurable biological signaling.
November 26, 2025 at 12:26 AM
The core hypothesis:
> a reproducible ratio of cannabinoids + terpenes can modulate pain pathways with consistent, clinically meaningful outcomes.
A mechanism grounded in compound interaction, and measurable biological signaling.
> a reproducible ratio of cannabinoids + terpenes can modulate pain pathways with consistent, clinically meaningful outcomes.
A mechanism grounded in compound interaction, and measurable biological signaling.
Most hemp derived products aren't built with scientific or regulatory intent.
Relieva changes that.
Using the New Leaf strain portfolio, it standardizes active cannabinoid and terpene compositions into a defined profile, delivering stable, reproducible pain-modulation effects.
Relieva changes that.
Using the New Leaf strain portfolio, it standardizes active cannabinoid and terpene compositions into a defined profile, delivering stable, reproducible pain-modulation effects.
November 26, 2025 at 12:26 AM
Most hemp derived products aren't built with scientific or regulatory intent.
Relieva changes that.
Using the New Leaf strain portfolio, it standardizes active cannabinoid and terpene compositions into a defined profile, delivering stable, reproducible pain-modulation effects.
Relieva changes that.
Using the New Leaf strain portfolio, it standardizes active cannabinoid and terpene compositions into a defined profile, delivering stable, reproducible pain-modulation effects.
Track, trade, and explore $GALE here:
molecule.xyz/ipts/gale?u...
molecule.xyz/ipts/gale?u...
Get GALE on Base | Live USD Price, Research Progress & Science Token Trading
Buy and track GALE via the latest price charts and scientific progress. biotech research IP token with governance rights. Live data on Molecule.xyz.
molecule.xyz
November 25, 2025 at 12:59 AM
Track, trade, and explore $GALE here:
molecule.xyz/ipts/gale?u...
molecule.xyz/ipts/gale?u...
this is what blockchain-native research on Molecule looks like:
> tackling a $1T disease burden with targeted, mechanism-level research.
> sharing every milestone publicly.
> building a clear path from lab to real-world translation.
> tackling a $1T disease burden with targeted, mechanism-level research.
> sharing every milestone publicly.
> building a clear path from lab to real-world translation.
November 25, 2025 at 12:59 AM
this is what blockchain-native research on Molecule looks like:
> tackling a $1T disease burden with targeted, mechanism-level research.
> sharing every milestone publicly.
> building a clear path from lab to real-world translation.
> tackling a $1T disease burden with targeted, mechanism-level research.
> sharing every milestone publicly.
> building a clear path from lab to real-world translation.
Every part of the work moves transparently through Molecule Labs -- all linked directly onchain to the $GALE token page.
> the entire research cycle, shared openly.
> the entire research cycle, shared openly.
November 25, 2025 at 12:59 AM
Every part of the work moves transparently through Molecule Labs -- all linked directly onchain to the $GALE token page.
> the entire research cycle, shared openly.
> the entire research cycle, shared openly.
Led by neuroscientist Dr. Maryna Polyakova and translational medicine expert Dr. Peter Groenen from @Cerebrum_DAO, the protocol includes:
> dosing Alzheimer's-model mice with a high specificity galectin-3 inhibitor
> tracking biological changes over 4 weeks
> brain tissue analysis
> dosing Alzheimer's-model mice with a high specificity galectin-3 inhibitor
> tracking biological changes over 4 weeks
> brain tissue analysis
November 25, 2025 at 12:59 AM
Led by neuroscientist Dr. Maryna Polyakova and translational medicine expert Dr. Peter Groenen from @Cerebrum_DAO, the protocol includes:
> dosing Alzheimer's-model mice with a high specificity galectin-3 inhibitor
> tracking biological changes over 4 weeks
> brain tissue analysis
> dosing Alzheimer's-model mice with a high specificity galectin-3 inhibitor
> tracking biological changes over 4 weeks
> brain tissue analysis
Galectin-3, a protein that drives chronic neuroinflammation, is strongly associated with cognitive decline and Alzheimer's pathology.
$GALE tests a simple but powerful hypothesis:
> silencing galectin-3 may slow or even reverse inflammatory damage in the brain.
$GALE tests a simple but powerful hypothesis:
> silencing galectin-3 may slow or even reverse inflammatory damage in the brain.
November 25, 2025 at 12:59 AM
Galectin-3, a protein that drives chronic neuroinflammation, is strongly associated with cognitive decline and Alzheimer's pathology.
$GALE tests a simple but powerful hypothesis:
> silencing galectin-3 may slow or even reverse inflammatory damage in the brain.
$GALE tests a simple but powerful hypothesis:
> silencing galectin-3 may slow or even reverse inflammatory damage in the brain.
Interested in talking at DeSci Abu Dhabi → moleculeprotocol.typeform.com/desciabudhabi
DeSci Abu Dhabi
Turn data collection into an experience with Typeform. Create beautiful online forms, surveys, quizzes, and so much more. Try it for FREE.
moleculeprotocol.typeform.com
November 24, 2025 at 1:29 PM
Interested in talking at DeSci Abu Dhabi → moleculeprotocol.typeform.com/desciabudhabi
connect with the community → @NEURONGale
track & trade the science → molecule.xyz/ipts/gale
track & trade the science → molecule.xyz/ipts/gale
November 21, 2025 at 11:51 AM
connect with the community → @NEURONGale
track & trade the science → molecule.xyz/ipts/gale
track & trade the science → molecule.xyz/ipts/gale
With over 150 million projected Alzheimer’s cases by 2050 and trillions in economic impact, even incremental progress in early-stage or disease-modifying interventions could be transformative.
November 21, 2025 at 11:51 AM
With over 150 million projected Alzheimer’s cases by 2050 and trillions in economic impact, even incremental progress in early-stage or disease-modifying interventions could be transformative.
The experiment is being led by Dr. Maryna Polyakova and Dr. Peter Groenen from the @Cerebrum_DAO team.
→ Maryna’s expertise spans neuroscience, neuroimaging, & machine learning
→ Peter brings decades of pharma R&D experience in translational medicine & biomarker development
→ Maryna’s expertise spans neuroscience, neuroimaging, & machine learning
→ Peter brings decades of pharma R&D experience in translational medicine & biomarker development
November 21, 2025 at 11:51 AM
The experiment is being led by Dr. Maryna Polyakova and Dr. Peter Groenen from the @Cerebrum_DAO team.
→ Maryna’s expertise spans neuroscience, neuroimaging, & machine learning
→ Peter brings decades of pharma R&D experience in translational medicine & biomarker development
→ Maryna’s expertise spans neuroscience, neuroimaging, & machine learning
→ Peter brings decades of pharma R&D experience in translational medicine & biomarker development
All of it - the protocol, updates, data, and results - will be published directly onchain, linked to the GALE token via Molecule Labs infrastructure.
We are moving into the future of a fully transparent, blockchain-native research process.
We are moving into the future of a fully transparent, blockchain-native research process.
November 21, 2025 at 11:51 AM
All of it - the protocol, updates, data, and results - will be published directly onchain, linked to the GALE token via Molecule Labs infrastructure.
We are moving into the future of a fully transparent, blockchain-native research process.
We are moving into the future of a fully transparent, blockchain-native research process.
Using a highly specific galectin-3 inhibitor, the team will dose mice with Alzheimer’s, tracking:
→ biological changes over 4 weeks
→ brain tissue for inflammation, plaque, and Alzheimer’s markers
→ full data analysis + final report
→ a follow-on funding decision
→ biological changes over 4 weeks
→ brain tissue for inflammation, plaque, and Alzheimer’s markers
→ full data analysis + final report
→ a follow-on funding decision
November 21, 2025 at 11:51 AM
Using a highly specific galectin-3 inhibitor, the team will dose mice with Alzheimer’s, tracking:
→ biological changes over 4 weeks
→ brain tissue for inflammation, plaque, and Alzheimer’s markers
→ full data analysis + final report
→ a follow-on funding decision
→ biological changes over 4 weeks
→ brain tissue for inflammation, plaque, and Alzheimer’s markers
→ full data analysis + final report
→ a follow-on funding decision
tldr --
NEURON-GALE is targeting Alzheimer's Disease through a unique pathway; by silencing a protein called galectin-3, which is linked to inflammation in the brain.
molecule.xyz/ipts/gale
NEURON-GALE is targeting Alzheimer's Disease through a unique pathway; by silencing a protein called galectin-3, which is linked to inflammation in the brain.
molecule.xyz/ipts/gale
Get GALE on Base | Live USD Price, Research Progress & Science Token Trading
Buy and track GALE via the latest price charts and scientific progress. biotech research IP token with governance rights. Live data on Molecule.xyz.
molecule.xyz
November 21, 2025 at 11:50 AM
tldr --
NEURON-GALE is targeting Alzheimer's Disease through a unique pathway; by silencing a protein called galectin-3, which is linked to inflammation in the brain.
molecule.xyz/ipts/gale
NEURON-GALE is targeting Alzheimer's Disease through a unique pathway; by silencing a protein called galectin-3, which is linked to inflammation in the brain.
molecule.xyz/ipts/gale